In April 2017, DNDi and GSK entered into an agreement for the pre-clinical development of two compounds for leishmaniasis that were developed through a collaboration between the GSK Global Health Unit and the Drug Discovery Unit at the University of Dundee, with co-funding support from Wellcome. In February 2020, DNDi and GSK signed a development and licence agreement for GSK3494245/3186899. 

Project updates

2021

A Phase I combined single ascending dose and multiple ascending dose study of GSK3494245/DDD1305143 in healthy volunteers began in late 2020 and continued in 2021, but faced delays due to the COVID-19 pandemic. It is now expected to be completed by mid-2022. GSK stopped development efforts on GSK3186899/DDD853651 in September 2021, giving DNDi the option to continue further development of the compound – a decision about which will be made in 2022.  

2020

A Phase I single ascending dose study of GSK3494245/DDD1305143 in healthy volunteers began in late 2020 and is expected to be completed by Q3 2021. A Phase I multiple ascending dose study of GSK3186899/DDD853651 in healthy volunteers is planned, pending funding and Global Safety Board approval.

2019

A Phase I single ascending dose study of GSK3186899/DDD853651 in healthy volunteers was completed in 2019; a Phase I single ascending dose study of GSK3494245/DDD1305143 is planned to start in late 2020.

2018

GSK3186899/DDD853651 was nominated as a clinical candidate in 2018. GSK3494245/DDD1305143 is currently under review to assess the feasibility of proceeding to a Phase I study.